Fever of unknown origin (FUO) defined as community-acquired fever of ≥38.3°C lasting ≥3 weeks in immunocompetent individuals generally excludes fever among hospitalized patients or patients with human immunodeficiency virus infection or neutropenia. Due to recent advances in diagnostic technology, including sophisticated imaging tests, improved culture techniques, and molecular diagnostics, there has been increase in cases reported with pathogens previously considered uncommon. At the same time, the realisation that new and subtle forms of immunodeficiency may present in adulthood has prompted practitioners to pursue immunological investigations earlier in the diagnostic workup of infections with unusual pathogens than was done previously. We present a case with FUO in which the isolation of an unexpected pathogen revealed an immunodeficient state that has been recently identified and has long term implications for the patient. We discuss the microbiological findings and laboratory investigations necessary to define the immune deficiency.
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CASE REPORT
A 28-year-old Indian man who had been living in Australia for the preceding 3 years, presented to the hospital with a 2-month febrile illness characterized by headaches, abdominal pain, night sweats, and 30kg of weight loss. He reported no significant medical history, medication use, or allergies. At physical examination, he had a fever of 38.3°C and palpable right cervical lymphadenopathy. Initial laboratory testing revealed marked leukocytosis, neutrophilia, and eosinophilia (white blood cell, neutrophil, and eosinophil counts, 32. The patient's enlarged cervical lymph node was excised for diagnostic testing and empiric treatment for disseminated tuberculosis infection was begun (with isoniazid, rifampicin, pyrazinamide, and ethambutol), including corticosteroids for presumed meningitis. Lymph node culture identified Mycobacterium abscessus complex, but its clinical significance was unclear given a single isolation ( Figure 1 ). After a brief period of stability, the patient's condition deteriorated, with recrudescence of fever, intractable headaches, and epigastric pain. Whole-body F 18 fluodeoxyglucose (FDG) positron emission tomography/CT scanning revealed an enlarged, mesenteric abdominal lymph node with increased FDG uptake (Figure 2) . Histopathology of this sample after surgical excision showed suppurative lymphadenitis without granulomatous inflammation. M. abscessus complex was again cultured, establishing a diagnosis of disseminated M. abscessus infection.
Guided by susceptibility testing of the original isolate, an antimicrobial regimen of intravenous cefoxitin, tigecycline, and amikacin was begun. The patient showed clinical improvement with resolution of inflammatory markers and weight gain. Disseminated nontuberculous mycobacterium (NTM) infection in a previously healthy individual prompted investigation for immunodeficiency, the results of which were consistent with serum neutralizing autoantibodies to either IFN-γ (anti-IFN-γ Abs) or its receptor ( Figure 3 ) [1, 2] . Approximately 18 months later, the patient has completed 2 courses of rituximab and 10 months of antimicrobial therapy, with no evidence of disease recurrence.
DISCUSSION
The clinical entity of adult-onset disseminated NTM infection resulting from anti-IFN-γ Abs is described in adults of Southeast or East Asian descent with a median age of 48 years [1, 3, 4] . Here we report the first case, to our knowledge, of anti-IFN-γ Abs arising in an individual of Indian origin. Genetic factors include a strong association with the HLA class II alleles DRB1*16 and DQB1*5, initially reported in a Taiwanese cohort, and DRB1*15, later reported in Thai patients [5] [6] [7] . We did not perform HLA analysis in our patient, but previous large-scale population studies have shown DRB1*15 as a common allele among individuals from Asian countries, including India, Taiwan, and Thailand [8] .
Disseminated NTM infection is the most common infection in individuals with anti -IFN-γ Abs [5] . Frequently isolated organisms include Mycobacterium avium complex, M. abscessus complex, and Mycobacterium fortuitum [3] . Herpesvirus reactivations and certain bacterial infections, such as nontyphoidal Salmonella, have also been described [3] . M. abscessus complex comprises a group of rapidly growing and multidrug-resistant NTM, found widespread in the environment. Infection in humans can result in a range of different clinical manifestations, although skin and soft-tissue and pulmonary infections seem most common [9] .
At present, there are no evidence-based guidelines regarding the specific treatment of this type of immunodeficiency. Previous uncontrolled case series include reports of treatment with intravenous immunoglobulin, plasmapheresis, cyclophosphamide, and exogenous IFN-γ to diminish the activity of anti-IFN-γ Abs [3] . Other case series have shown therapeutic benefit with the anti-CD20 monoclonal antibody rituximab [10, 11] . Our patient received 2 doses of rituximab over a 1-month period with continued antimicrobial therapy (10 months in total), after an initial period of 6 months of antimicrobial therapy alone to minimize the chance of recurrence.
In our patient, disseminated M. abscessus infection mimicked the typical clinical manifestations of disseminated tuberculosis and was initially treated as such. There is evidence suggesting that the QuantiFERON-TB Gold assay, which in this setting results in subnormal responses to mitogens, may serve as a screening tool for anti-IFN-γ Ab activity in similar presentations [12, 13] . The test can be especially useful in resource-poor settings where specialized assays to measure IFN-γ activity are not available. Collecting suitable tissue samples for diagnostic testing is also critical, and FDG positron emission tomography/ CT allowed for a targeted biopsy to better direct management [14, 15] .
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